Reuters logo
BRIEF-Seres Therapeutics reports positive topline results from ser-287 phase 1b study in patients with ulcerative colitis
October 2, 2017 / 11:11 AM / 20 days ago

BRIEF-Seres Therapeutics reports positive topline results from ser-287 phase 1b study in patients with ulcerative colitis

Oct 2 (Reuters) - Seres Therapeutics Inc:

* Seres Therapeutics reports positive topline results from ser-287 phase 1b study in patients with ulcerative colitis

* Seres Therapeutics Inc - ‍no clinically significant safety or tolerability findings were observed​

* Seres - ‍ser-287 microbiome treatment resulted in a dose-dependent benefit in clinical remission rates, and an improvement in endoscopic scores​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below